Loading…
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-438M | $-414M | $-377M | -58.5% | - | - |
| 2024 | $0M | $-270M | $-259M | $-215M | -42.0% | - | - |
| 2023 | $0M | $-208M | $-211M | $-188M | -58.2% | - | - |
| 2022 | $0M | $-156M | $-157M | $-106M | -33.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 156.03 | 208.28 | 270.21 | 438.15 |
| Operating Income | -156.03 | -208.28 | -270.21 | -438.15 |
| EBITDA | -155.91 | -208.08 | -269.98 | -437.77 |
| EBIT | -156.03 | -208.28 | -270.21 | -438.15 |
| Pretax Income | -156.81 | -210.95 | -258.77 | -412.95 |
| Tax Provision | -0.08 | 0.01 | 0.57 | 0.89 |
| Net Income | -156.73 | -210.96 | -259.34 | -413.84 |
| Net Income Common Stockholders | -156.73 | -210.96 | -259.34 | -413.84 |
| Total Expenses | 156.03 | 208.28 | 270.21 | 438.15 |
| Interest Income | 0 | 7.58 | 24.95 | 24.73 |
| Research And Development | 101.81 | 160.26 | 212.93 | 360.92 |
| Selling General And Administration | 54.23 | 48.02 | 57.28 | 77.23 |
| Normalized EBITDA | -155.91 | -198.08 | -257.48 | -437.77 |
| Normalized Income | -156.73 | -200.96 | -249.46 | -413.84 |
| Basic EPS | -1.43 | -1.71 | -1.88 | -2.73 |
| Diluted EPS | -1.43 | -1.71 | -1.88 | -2.73 |
| Tax Effect Of Unusual Items | 0 | 0 | -2.62 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.21 |
| Total Unusual Items | 0 | -10 | -12.50 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | -10 | -12.50 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -156.73 | -210.96 | -259.34 | -413.84 |
| Reconciled Depreciation | 0.13 | 0.19 | 0.23 | 0.38 |
| Net Interest Income | 0 | 7.58 | 24.95 | 24.73 |
| Net Income From Continuing And Discontinued Operation | -156.73 | -210.96 | -259.34 | -413.84 |
| Diluted Average Shares | 109.68 | 123.08 | 138.10 | 151.57 |
| Basic Average Shares | 109.68 | 123.08 | 138.10 | 151.57 |
| Diluted NI Availto Com Stockholders | -156.73 | -210.96 | -259.34 | -413.84 |
| Net Income Including Noncontrolling Interests | -156.73 | -210.96 | -259.34 | -413.84 |
| Net Income Continuous Operations | -156.73 | -210.96 | -259.34 | -413.84 |
| Other Income Expense | -0.78 | -10.25 | -13.51 | 0.47 |
| Other Non Operating Income Expenses | -0.78 | -0.25 | -1.01 | 0.47 |
| Special Income Charges | 0 | -10 | -12.50 | 0 |
| Other Special Charges | 0 | 10 | 12.50 | 0 |
| Restructuring And Mergern Acquisition | 0 | 10 | 12.50 | 0 |
| Net Non Operating Interest Income Expense | 0 | 7.58 | 24.95 | 24.73 |
| Interest Income Non Operating | 0 | 7.58 | 24.95 | 24.73 |
| General And Administrative Expense | 54.23 | 48.02 | 57.28 | 77.23 |
| Other Gand A | 54.23 | 48.02 | 57.28 | 77.23 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Immunovant, Inc.this co. | IMVT | $5.5B | - | 5.56 | -58.5% | -9.23 |
| Mirum Pharmaceuticals, Inc. | MIRM | $5.7B | - | 15.53 | -7.4% | 2666.18 |
| CG Oncology, Inc. | CGON | $5.7B | - | 6.94 | -21.4% | -24.99 |
| Rhythm Pharmaceuticals, Inc. | RYTM | $5.6B | - | 39.69 | -72.8% | -28.64 |
| Scholar Rock Holding Corporation | SRRK | $5.5B | - |
| 20.46 |
| -154.0% |
| -13.21 |
| Oscar Health, Inc. | OSCR | $5.4B | - | 5.45 | -45.2% | -5.02 |
| Xenon Pharmaceuticals Inc. | XENE | $5.4B | - | 7.67 | -59.5% | -11.06 |
| Lantheus Holdings, Inc. | LNTH | $5.3B | 23.80 | 4.81 | 21.4% | 14.41 |
| PACS Group, Inc. | PACS | $5.2B | 27.38 | 5.53 | 20.1% | 23.70 |
| Peer Median | - | 25.59 | 7.30 | -33.3% | -8.04 | |